Arihant School of Pharmacy & BRI, Gandhinagar, Gujarat, India.
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
Daru. 2019 Jun;27(1):59-70. doi: 10.1007/s40199-019-00242-x. Epub 2019 Jan 30.
Clinical utility of lornoxicam in oral therapy is primarily restricted by the low solubility and gastric adverse effects. This study evaluated the prospective of optimized proniosomal gel to improve the clinical efficacy of lornoxicam and compare with oral therapy.
Proniosomes were formulated by coacervation phase separation technique using span 60, lecithin and cholesterol. A four-factor three-level Box-Behnken design was used to evaluate the effect of amount of four independent variables; span 60 (X), cholesterol (X), lecithin (X) and lornoxicam (X) on response variables; vesicle size (Y), entrapment efficiency (Y) and transdermal flux (Y). The selected proniosomal gel (F19) was characterized, and evaluated for the transdermal efficacy by ex vivo and in vivo experiments.
Optimization study signifies that amount of formulation components (span 60, cholesterol, lecithin and lornoxicam) influence the vesicle size, entrapment efficiency and/or transdermal flux. Optimized formulation F19 exhibited nano size with high entrapment efficiency, adequate zeta potential, greater transdermal flux and better stability (at refrigerated conditions). The entrapment of lornoxicam in the bilayers of proniosome vesicles was confirmed by differential scanning calorimeter. Release profile of F19 was distinct (p < 0.001) from gel prepared using hydroxypropyl methylcellulose (control) and displayed steady lornoxicam release by Fickian diffusion. Transdermal administration of F19 significantly inhibited the carrageenan induced hind-paw edema in rats as compared to oral lornoxicam group.
The data observed in this study demonstrated that the developed proniosomal gel (F19) improved the clinical efficacy of lornoxicam as compared to oral therapy. Graphical Abstract Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats.
氯诺昔康口服治疗的临床实用性主要受到低溶解度和胃部不良反应的限制。本研究评估了优化前体囊泡凝胶的前景,以提高氯诺昔康的临床疗效,并与口服治疗进行比较。
采用凝聚相分离技术,用司盘 60、卵磷脂和胆固醇制备前体囊泡。采用四因素三水平 Box-Behnken 设计,考察四个独立变量(司盘 60(X)、胆固醇(X)、卵磷脂(X)和氯诺昔康(X))对响应变量(囊泡粒径(Y)、包封率(Y)和透皮通量(Y))的影响。对选定的前体囊泡凝胶(F19)进行了表征,并通过离体和体内实验评价了其透皮效果。
优化研究表明,制剂成分(司盘 60、胆固醇、卵磷脂和氯诺昔康)的用量影响囊泡粒径、包封率和/或透皮通量。优化后的 F19 制剂表现出纳米级尺寸、高包封率、合适的 Zeta 电位、较大的透皮通量和更好的稳定性(在冷藏条件下)。差示扫描量热法证实氯诺昔康被包封在前体囊泡的双层中。F19 的释放曲线与使用羟丙基甲基纤维素(对照)制备的凝胶明显不同(p<0.001),并通过菲克扩散显示出稳定的氯诺昔康释放。与口服氯诺昔康组相比,F19 的透皮给药显著抑制了角叉菜胶诱导的大鼠后爪水肿。
本研究观察到的数据表明,与口服治疗相比,所开发的前体囊泡凝胶(F19)提高了氯诺昔康的临床疗效。